INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 231 filers reported holding INOVIO PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.28 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,300 | -14.3% | 36,760 | -1.5% | 0.00% | -100.0% |
| Q2 2023 | $16,680 | +30227.3% | 37,316 | -44.4% | 0.00% | -50.0% |
| Q1 2023 | $55 | +57.1% | 67,084 | +198.7% | 0.00% | +100.0% |
| Q4 2022 | $35 | -100.0% | 22,455 | -82.6% | 0.00% | -75.0% |
| Q3 2022 | $222,000 | +101.8% | 129,084 | +101.8% | 0.00% | +100.0% |
| Q2 2022 | $110,000 | -33.3% | 63,972 | +39.6% | 0.00% | 0.0% |
| Q1 2022 | $165,000 | -60.1% | 45,832 | -44.8% | 0.00% | -71.4% |
| Q4 2021 | $414,000 | -4.8% | 83,059 | +36.7% | 0.01% | -36.4% |
| Q3 2021 | $435,000 | +405.8% | 60,758 | +554.6% | 0.01% | +450.0% |
| Q2 2021 | $86,000 | -45.2% | 9,281 | -45.1% | 0.00% | -33.3% |
| Q1 2021 | $157,000 | +214.0% | 16,913 | +201.5% | 0.00% | +50.0% |
| Q4 2020 | $50,000 | -90.8% | 5,609 | -88.1% | 0.00% | -66.7% |
| Q3 2020 | $545,000 | -9.9% | 46,976 | +109.2% | 0.01% | -76.0% |
| Q2 2020 | $605,000 | +7462.5% | 22,452 | +474.4% | 0.02% | +2400.0% |
| Q3 2019 | $8,000 | +33.3% | 3,909 | +97.2% | 0.00% | – |
| Q2 2019 | $6,000 | +200.0% | 1,982 | +252.0% | 0.00% | – |
| Q4 2018 | $2,000 | -96.9% | 563 | -95.9% | 0.00% | -100.0% |
| Q1 2018 | $65,000 | +983.3% | 13,808 | +922.8% | 0.01% | +500.0% |
| Q4 2017 | $6,000 | -87.8% | 1,350 | -82.7% | 0.00% | -75.0% |
| Q3 2017 | $49,000 | +81.5% | 7,786 | +99.0% | 0.00% | +33.3% |
| Q4 2016 | $27,000 | +440.0% | 3,912 | +682.4% | 0.00% | – |
| Q3 2016 | $5,000 | -58.3% | 500 | -61.0% | 0.00% | -100.0% |
| Q2 2016 | $12,000 | +500.0% | 1,283 | +608.8% | 0.00% | – |
| Q1 2016 | $2,000 | -89.5% | 181 | -93.5% | 0.00% | -100.0% |
| Q4 2015 | $19,000 | -94.3% | 2,803 | -95.2% | 0.00% | -90.9% |
| Q3 2015 | $335,000 | +805.4% | 57,914 | +1178.5% | 0.03% | +1000.0% |
| Q2 2015 | $37,000 | -57.0% | 4,530 | -57.1% | 0.00% | -72.7% |
| Q1 2015 | $86,000 | +8500.0% | 10,571 | +8935.0% | 0.01% | – |
| Q3 2014 | $1,000 | -98.2% | 117 | -97.7% | 0.00% | -100.0% |
| Q2 2014 | $55,000 | – | 5,117 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON ASSOCIATES LP | 784,679 | $643,437 | 0.10% |
| Green Alpha Advisors, LLC | 146,300 | $119,966 | 0.08% |
| Virtus ETF Advisers LLC | 54,106 | $44,367 | 0.02% |
| Cedar Brook Financial Partners, LLC | 104,881 | $86,002 | 0.02% |
| PROFUND ADVISORS LLC | 418,749 | $343,374 | 0.02% |
| Arlington Capital Management, Inc. | 27,735 | $22,743 | 0.02% |
| Hennion & Walsh Asset Management, Inc. | 382,158 | $313 | 0.02% |
| Rafferty Asset Management, LLC | 2,647,927 | $2,171,300 | 0.02% |
| Brainard Capital Management LLC | 16,666 | $13,666 | 0.01% |
| Beck Bode, LLC | 41,218 | $33,799 | 0.01% |